A phase I clinical study of a cocktail vaccine of Wilms ’ tumor 1 (WT1) HLA class I and II peptides for recurrent malignant glioma
ConclusionThe safety of a cocktail vaccine of WT1 HLA class I and II peptides for malignant gliomas was verified. This vaccine is, therefore, considered promising for patients with recurrent malignant glioma.
Source: Cancer Immunology, Immunotherapy - Category: Cancer & Oncology Source Type: research
More News: Allergy & Immunology | Brain Tumor | Cancer | Cancer & Oncology | Cancer Vaccines | Clinical Trials | Glioma | Immunotherapy | Skin | Study | Toxicology | Vaccines